The recommendation, published in The BMJ, states that multiple clinical trials of more than 6,000 people have shown that hydroxychloroquine has no meaningful effect on death or hospital admissions in people with no prior exposure to COVID-19, according to The Hill.
The trials also showed a “moderate certainty” that hydroxychloroquine increases the risk of adverse effects.
“The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent COVID-19,” the WHO said.
Hydroxychloroquine is FDA approved to treat malaria, lupus and rheumatoid arthritis.
More articles on pharmacy:
How J&J’s COVID-19 vaccine compares to Moderna’s, Pfizer’s
Merck to manufacture J&J’s COVID-19 vaccine
Florida expands eligibility for COVID-19 vaccines at retail pharmacies, physician offices
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
